Wells Fargo & Company Kal Vista Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 15,622 shares of KALV stock, worth $139,973. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,622
Previous 15,932
1.95%
Holding current value
$139,973
Previous $187,000
3.74%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding KALV
# of Institutions
125Shares Held
47.8MCall Options Held
551KPut Options Held
110K-
Vr Adviser, LLC New York, NY6.25MShares$56 Million7.5% of portfolio
-
Tang Capital Management LLC San Diego, CA4.32MShares$38.7 Million4.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.21MShares$37.7 Million1.92% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$35.8 Million3.51% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$33 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $220M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...